The GENIE Consortium is comprised of 20 leading international cancer centers dedicated to advancing prevision oncology through collaborative data sharing and research. As a legal consortium with collective data sharing rights, it forms the foundation of GENIE services enabling: 

• Customized Research Solutions – Tailored studies (retrospective, prospective, or hybrid) addressing key industry needs. 
• Comprehensive Support Across the Drug Development Lifecycle – From preclinical discovery through post-market surveillance. 
• Regulatory-Grade Data – High-quality RWD that aligns with data used in late-stage clinical trials. 

By combining the strengths of its Registry and Consortium, GENIE delivers an integrated ecosystem for scalable, high-quality oncology RWD solutions, ensuring that industry partners can accelerate innovation with clinically relevant, deeply curated datasets.